MARKET

PODD

PODD

Insulet Corp
NASDAQ
190.88
-3.50
-1.80%
Pre Market: 212.00 +21.12 +11.06% 06:51 07/26 EDT
OPEN
192.62
PREV CLOSE
194.38
HIGH
197.55
LOW
190.64
VOLUME
2.26K
TURNOVER
0
52 WEEK HIGH
293.64
52 WEEK LOW
125.82
MARKET CAP
13.37B
P/E (TTM)
59.43
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Insulet rises on better-than-expected prelim Q2 revenue
Shares of Insulet Corp rise 5.5% to $201.42 premarket. Medical device maker's prelim Q2 rev of $488 mln is above Wall Street estimates of $460.3 mln. Prelim Q2 sales of Omnipod, its tubeless insulin pump, are above estimates.
Reuters · 15h ago
Insulet Lifts 2024 Revenue Target After Insulin Pump Beat 2Q Sales Views
Dow Jones · 15h ago
Insulet stock falls even as prelim Q2 revenue tops estimates
Insulet stock falls even as prelim Q2 revenue tops estimates of $488M. The medical device company firm reported preliminary results for the second quarter of 2024. Insulet shares fell around 6% in early trade on Friday after the company reported preliminary revenue up 23% Y/Y.
Seeking Alpha · 15h ago
*Insulet: Expect to Raise Its Full Yr 2024 Total Omnipod Rev Outlook to Range of 18% to 21% Vs Prior Range 15% to 19%, When It Releases Its Full Fincl Results on Aug 8 >PODD
Dow Jones · 15h ago
*Insulet Sees 2Q U.S. Omnipod Rev of $352M >PODD
Dow Jones · 15h ago
*Insulet Sees 2Q Total Omnipod Rev of $480M >PODD
Dow Jones · 15h ago
*Insulet Sees 2Q International Omnipod Rev of $128M >PODD
Dow Jones · 15h ago
Insulet Reports Preliminary Q2 Revenue Of $488M (Est $460.275M), Up 23% Y/Y, Exceeds Guidance Range Of 15% - 18% In Constant Currency Due To Revenue Outperformance For All Product Lines
"Second quarter revenue exceeded our expectations across the board," says Insulet CEO. The company says Omnipod 5 is driving strong demand for the company's new product line. InSulet says it expects to be profitable for the rest of 2024.
Benzinga · 15h ago
More
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.

Webull offers Insulet Corp stock information, including NASDAQ: PODD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PODD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PODD stock methods without spending real money on the virtual paper trading platform.